Predicting response to treatment in patients with inflammatory bowel disease (ECCO Grant)

The introduction of new non-anti-TNF agents such as the anti-adhesion and anti-IL-12/IL-23 molecules will increase the therapeutic armamentarium for patients with IBD. It is nevertheless anticipated that clinical response and adverse events will vary significantly between individuals. Therefore, we need predictors of efficacy and safety, so we can select the right drug at the right time for the right patient. Targeted strategies in patients with poor prognostic factors and head-to-head trials are currently missing.The ultimate objective of this project is the development of a comprehensive algorithm to direct individualized medicine. Therefore we will explore which clinical, endoscopic, genetic, transcriptomic and microbial factors are influencing response to and safety of existing and novel therapeutic modalities.